(Q44579054)

4 December 2017

Efficacy of acarbose in Chinese subjects with impaired glucose tolerance (English)

1 reference

4 December 2017

Chang-Yu Pan

1

1 reference

4 December 2017

Yan Gao

2

1 reference

4 December 2017

Jia-Wei Chen

3

1 reference

4 December 2017

Bang-Yao Luo

4

1 reference

4 December 2017

Zu-Zhi Fu

5

1 reference

4 December 2017

Ju-Ming Lu

6

1 reference

4 December 2017

Xiao-Hui Guo

7

1 reference

4 December 2017

Hua Cheng

8

1 reference

4 December 2017

1 September 2003

1 reference

Diabetes Research and Clinical Practice

4 December 2017

1 reference

4 December 2017

61

1 reference

4 December 2017

3

1 reference

4 December 2017

183-190

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

The clinical implications of impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

The post-prandial state and cardiovascular disease: relevance to diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2803%2900117-7

7 January 2021

10.1016/S0168-8227(03)00117-7

Identifiers

DOI

1 reference

4 December 2017

1 reference